Targeting CCL5 in inflammation

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Chemokines, including C-C chemokine ligand 5 (CCL5), are crucial in regulating inflammation and immune responses.
• CCL5's role in allergic, autoimmune, and infectious diseases is under investigation as a potential therapeutic target.

Purpose of the Study:

• To review the current literature on C-C chemokine ligand 5 (CCL5).
• To evaluate CCL5 and its receptors as therapeutic targets for various diseases.

Main Methods:

• Utilized small-molecule inhibitors, genetically modified mice (chemokine and receptor-deficient), antibodies, and modified chemokines for CCL5 research.
• Reviewed ongoing clinical trials targeting CCL5 receptors (CCR1, CCR3, CCR5) and discussed the limited studies on targeting CCL5 directly.

Main Results:

• Clinical trials predominantly focus on CCR5 blockers for HIV treatment and prevention.
• Research indicates limited efficacy of direct CCL5 targeting for infectious diseases with significant inflammation.

Conclusions:

• Targeting CCL5 presents potential for novel therapies in chronic inflammatory diseases, potentially reducing inflammation and fibrosis.
• CCL5 inhibition may offer therapeutic benefits in certain solid tumors by impacting angiogenesis.